Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
nPvds4UnLNK5KUNV
